http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Evotec Joins Forces with Academic Leaders to Accelerate Drug Discovery in Kidney Diseases and Build 'NEPLEX'
-
Evotec AG to Report First Nine-Month 2017 Results on 08 November 2017
-
Evotec and TESARO Enter Strategic Partnership to Discover Novel Immuno-Oncology Agents
-
Evotec Invests in Exscientia to Advance AI-Driven Drug Discovery
-
European Investment Bank Supports Evotec's Innovate Strategy with EUR 75 M Loan
-
Evotec and ABIVAX Enter into Strategic Collaboration to Develop Novel Antiviral Agents
-
ABIVAX and Evotec Enter into Strategic Collaboration to Develop Novel Antiviral Agents
-
Evotec to Attend Upcoming Investor Conferences
-
Evotec Completes Acquisition of Aptuit
-
Evotec Announces First Half Year 2017 Results and Corporate Update
-
Evotec AG to Report First Half-Year 2017 Results on 10 August 2017
-
Evotec and Fraunhofer IME-SP Sign Strategic Collaboration on IPSC Technology
-
Evotec to Acquire Aptuit, Expanding Leadership in External Innovation
-
Evotec Expands Collaboration with Storm Therapeutics on Its RNA Epigenetics Platform
-
Evotec and Bayer Advance Endometriosis Programme into Phase I Clinical Development and Extend Alliance
-
Evotec Received Funding from IFB Hamburg to Identify Antibody-Mediated T-cell Immunotherapies
-
Evotec Expands iPSC Drug Discovery Leadership Through Strategic Collaboration with Censo Biotechnologies
-
Evotec AG: LAB282 Accelerates with Second Round Funding
-
Evotec Announces Strategic Investment in Facio Therapies to Support Development of Novel FSHD Therapy
-
Resolutions of the Annual General Meeting 2017 of Evotec AG
-
Evotec Joins NURTuRE Consortium to Mine Unique Kidney Disease Patient Biobank
-
Evotec Receives Pre-Clinical Milestone as Part of Its Endometriosis Alliance with Bayer
-
Forge Therapeutics Attracts Biotechnology Leaders To Join Expanded Board Of Directors
-
Evotec to Attend Three Upcoming Investor Conferences
-
Evotec Announces First Quarter 2017 Results and Corporate Update
-
Evotec AG to Report First Quarter 2017 Results on 10 May 2017
-
Forge Therapeutics Raises $15M Series A Financing to Develop First Novel Gram-Negative Antibiotic in Decades
-
Evotec Achieves First Milestone in Diabetes Alliance with Sanofi
-
Evotec's Partner Forge Therapeutics Receives Prestigious CARB-X Research Award
-
Evotec AG: 'LAB282' Awarded First Projects
-
Evotec and UCB Sign Multi-Year Sample Management Agreement

